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Abstract 
Blockchains have the potential, if appropriately implemented and managed, of contributing to a fundamental change in the application 
of techniques of health technology assessment in formulary decision making. Rather than continuing to rely on claims made by 
manufacturers that are non-evaluable, the introduction of blockchains as adjunct to the electronic medical record, meet an unmet 
medical need in enabling a platform for the real time assessment of claims. Rather than focusing the case for their product on lifetime 
cost-per-QALY models, which have no chance of ever being validated, the blockchain platform offers a low cost opportunity for claims 
evaluation. Manufacturers would be required to abandon the construction of imaginary cost-per-QALY worlds to support claims for 
pricing and formulary trier position, in favor of claims that can be evaluated and reported back to formulary committees in a short yet 
meaningful time horizon. Manufacturers would present a claims assessment protocol as part of the formulary submission package. If 
agreed with the formulary committee, the protocol would be implemented and managed through the patient blockchain membership. 
Claims would be monitored and evaluated in real time with a final report to the formulary committee in a matter of months. Lifetime 
imaginary claims for cost-per-QALY, set alongside willingness-to-pay thresholds, would be a thing of the past. Pricing decisions and 
formulary placement would reflect a robust evidence base and not just extrapolations from pivotal clinical trials. 
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INTRODUCTION  
Establishing a robust evidence base to support, not only 
formulary decision making for new products and devices, but 
also to support ongoing disease and therapeutic class reviews 
is essential for effective health system management 1 2. 
Unfortunately, when new products and devices are proposed 
for formulary listing the evidence base is typically far from 
robust. Apart from the limitations imposed on claims for 
external validity that characterize phase 3 pivotal trials, claims 
presented are all too often extrapolated from trials with a 
limited time frame. Attendant claims for cost-effectiveness are 
all too often supported by modeled  frameworks that defy 
evaluation and replication. In previous commentaries in 
INNOVATIONS in Pharmacy the case has been made that the 
standards recommended for formulary submission reflect a 
willingness to extrapolate from limited clinical data to lifetime 
clinical and cost-outcomes models 3 The key criticism is that , 
irrespective of claims that the assumptions are ‘realistic’ 
constructing imaginary modeled worlds fail to meet the 
standards of normal science in generating credible, evaluable 
and replicable claims 4. This lack of scientific merit is 
exemplified in the US by the standards for formulary 
submissions advocated by groups such as the Academy of  
 
Corresponding author: Paul C Langley, PhD 
Adjunct Professor 
College of Pharmacy University of Minnesota 
Director, Maimon Research LLC 
5061 North Apache Hills Trail, Tucson, AZ 85750 
Email: langley@maimonresearch.com 
Managed Care Pharmacy (AMCP) and the International Society 
for Pharmacoeconomics and Outcomes Research (ISPOR) as 
well as by self-appointed arbiters of cost-effectiveness claims 5 
6. The last point is best exemplified by the reports prepared by 
the Institute for Clinical and Economic Review (ICER) 7. The ICER 
is wedded to the lifetime cost-per-QALY methodology that 
generates claims that are impossible to verify (by definition). 
The result, as detailed below, is that manufacturers respond by 
producing competing models which are claimed to be more 
realistic in their choice of lifetime modeled assumptions. The 
net result is a number of competing models that serve no other 
purpose than to ‘muddy’ the waters. Or, to put somewhat 
differently, a situation where various black box models 
compete for attention. 
 
The purpose of this commentary is to explore the potential 
implications for formulary evaluations of a health system 
adopting a blockchain platform that sits alongside the 
electronic medical record; a potential role that allows us to put 
to one side the construction of imaginary worlds to support 
formulary advocacy. Rather, we have the opportunity to move 
towards a formulary evaluation paradigm that rejects the 
standard approach to submissions in favor of one that 
emphasizes the need for competing drug and device claims that 
are realistic, evaluable and replicable in treating environments. 
A process that allows formulary committees to receive timely 
evaluations of claims for target patient populations within the 
approved indication that can be integrated in pricing and tier 
position decisions.  
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Blockchains, Property Rights and Security 
The technical merits of blockchains are now, after some ten 
years since their first introduction to support cryptocurrency 
exchanges, well established. They offer a secure, encrypted 
data environment which overcomes, from the patient’s 
perspective, concerns with the security of their personal health 
and medical records. Subject to agreement on property rights 
to medical records and the transfer of records to the 
blockchain, the prospect opens up for the patient, subject to 
the appropriate permissions and ‘smart contracts’, to monetize 
their data via tokenization. Additionally, the patient also has the 
opportunity to value add to their record by participating in 
studies that support assessments of therapy responses.  
 
Two previous have explored the range of activities that 
blockchain platforms could support in health technology 
assessment including formulary evaluations 8  9.  
It is this last prospect, supporting studies that evaluate claims 
for competing products and devices, as well as new products, 
that offers formulary committees a more robust evidence base 
for pricing and tier positioning.  
 
Even so, it should be cautioned that the ability to support claims 
assessments, as detailed in our previous commentary, 
presupposes the role of a managed market coordinator. The 
blockchain owner, or a sub-contractor, would have the task of 
acting as a market intermediary between the health system 
formulary, the manufacturer, providers and patients. This is a 
necessary condition for the blockchain platform to realize its 
potential with the owner as agent for the patients subscribing 
to the blockchain. A primary task for the blockchain owner, as 
agent, would be to identify target patient population within the 
platform and to solicit their agreement for monetized study 
participation.  
 
Blockchain Incentives 
Who benefits from the blockchain platform? If we accept the 
proposition that the blockchain is ‘free’ to the patient who is  
encouraged to participate through secure encryption and 
prospective monetization of their health data, the issue is then 
one of incentivizing the other participants: the health system 
and the provider.  
 
If we focus on the role of the blockchain platform as a necessary 
element in formulary evaluations, then the potential benefits 
to the health system in subscribing to the blockchain  (e.g., for 
profit HMO) lies in the ability of the health system to generate, 
in real-time, a platform for evaluating claims for competing 
products for target patient groups. These would have the 
potential for monitoring patients’ response and switching 
interventions leading to improved outcomes in target 
populations and reduced resource misallocation. A robust 
claims assessment potential would put health systems in the 
pole position in negotiating prices. Rather than rely on a 
modeled claim, there would be real world evidence (RWE) to 
judge the merits of competing products. This feedback could 
also be counter to the practice of manufacturers announcing 
annual or semi-annual price increases where there is no clinical 
justification. Indeed, a blockchain monitoring system would 
enable closer targeting of patients who are expected to benefit, 
supported by programs to improve adherence and reduce 
discontinuation.  
 
The option of developing blockchain platforms in disease areas 
also offers a secure base for risk contracting with 
manufacturers. In the terms of both supporting platform claims 
assessment and utilizing the platform to support a risk sharing 
contract, the manufacturer (as detailed below) would be 
expected to meet all costs.  
 
The provider or physician practice plays a pivotal role in both 
the recruitment of patients to the blockchain, as well as, 
supporting value added evaluations of claims for new and 
competing products and devices. Options for provider 
incentives would include: (i) tokenization for study 
participation; (ii) enhanced practice revenue through 
participating in a study; (iii) as well as support through ongoing 
data transfers to the blockchain.  Potential revenue sources are 
from meeting CMS quality metric initiatives as the Federal 
government focuses on outcomes rather than process 
measures, and the possibility of capturing billable CPT codes 
from practice improved data collection (e.g., patient reported 
outcomes) and transfer of these data to the blockchain. 
 
Formulary Submission Standards 
Over the past almost 20 years the AMCP Format for Formulary 
Submissions has become the de facto standard for formulary 
submission in both public and commercial environments. This 
is unfortunate from the claims assessment perspective. While 
the format asks for a summary of the clinical attributes of the 
particular product, together with an assessment of its relative 
merits vis à vis comparator products, consideration is not given 
to claims assessment and replication in target populations or 
how the claims might be evaluated. This is a major oversight 
given the doubts that have been raised over the past decade 
and more that RCT based claims, even when the same protocol 
is used, have been impossible to replicate. 
 
Apart from the absence of recommendations for claims 
replication, the format recommends that, in making a claim for 
cost-effectiveness, manufacturers should present a model that 
tracks the natural course of a disease. The model should 
express outcomes in terms of cost-per-quality adjusted life year 
(QALYs) with modeled outcomes set against willingness-to-pay 
thresholds. Given uncertainties in model structure and model 
parameters a sensitivity analysis is recommended, with 
estimates of the probability of being cost-effective in terms of 
the unit price of the product. 
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Obviously, modeling over the lifetime of a target patient cohort 
– whose characteristics may be selected to enhance model 
claims – with a price that may similarly be chosen to support 
claims for cost-effectiveness and willingness-to-pay, is hardly a 
basis for effective formulary decision making. It is perhaps not 
surprising that formulary committees are suspicious of 
modeled claims, particularly when there is no chance of the 
claim ever being evaluated. The fact is that any modeled claim 
for cost-effectiveness to meet willingness-to-pay thresholds 
can be constructed. A price can be selected by the 
manufacturer simply to obtain formulary admission and, within 
a few months, revised to meet pricing strategy objectives. 
While this may seem an unduly cynical perspective in light of 
the resources devoted to modeling and the thousands of 
papers published over the past 30 or so years, the fact remains 
that in the absence of an acceptance of the standards of normal 
science reverse engineering is always possible. 
 
Unfortunately, the popularity of lifetime modeled claims seems 
impervious to the criticism that constructing imaginary claims 
fails to meet the standards of normal science. In part this 
reflects the fact that assessment agencies such as the National 
Institute for Health and Care Excellence (NICE) in the UK, as 
agent for the National Health Service (NHS) in England, 
mandate imaginary cost-per-QALY models to emulate the 
natural course of a disease 10. Indeed, the latest Canadian 
guideline for formulary submissions is quite clear that building 
imaginary worlds is for ‘information only’ 11. They are not 
interested in evaluating claims: Economic evaluations are 
designed to inform decisions. As such, they are distinct from 
conventional research activities, which are designed to test 
hypotheses. It is a moot point as to how the construction of 
imaginary worlds which may extend over decades (if intended 
to capture the natural course of a disease) are expected to 
inform decisions when, presumably, competing imaginary 
claims may also be submitted. In the absence of a commitment 
to evaluate claims through hypothesis testing it is difficult to 
see why formulary committees should take modeled claims for 
cost-effectiveness seriously.   
 
The Blockchain Alternative 
Rather than basing decisions on non-evaluable claims 
generated by imaginary worlds, the blockchain platform offers 
a robust evidentiary alternative. An alternative that is 
consistent with the standards of normal science for evaluation 
and replication of clinical and, in the short-term, cost-
effectiveness claims. The presence of a blockchain platform 
obviates the need to construct imaginary worlds. Rather than a 
manufacturer pleading with a formulary committee and even 
offering discounts to justify their model in contrast to 
competing models, the blockchain platform can support 
evaluation protocols.  
 
The requirement for manufacturers to support and underwrite 
evaluation protocols is central to the recently released 
Minnesota guideline for formulary submissions 2. Where a 
submission is prepared for a new product or to support ongoing 
disease area and therapeutic class reviews the manufacturer is 
asked to present as part of the submission a protocol describing 
how the clinical and cost-effectiveness claims are to be 
evaluated. Lifetime modeled claims are rejected; claims should 
be able to be evaluated in a short timeframe and the results 
reported back to the formulary committee. Until the results of 
the claims assessment protocol are available the product is 
granted provisional pricing and tier placement. 
 
With the blockchain property rights vested in the patient, 
implementing a claims assessment protocol will require the 
manufacturer to enter into monetized, smart contracts with 
target patient populations. Depending upon the data elements 
that are required to be captured, further agreement may have 
to be sought with providers to capture office assessed clinical 
endpoints. 
 
A key point to note is that the protocol is intended not only to 
evaluate but provide a forum to replicate claims generated by 
pivotal randomized clinical trials (RCTs), as closely as possible. 
Rather than taking RCT claims at face value, which is the case in 
the construction of imaginary worlds, requiring a claims 
protocol addresses the issue of non-replication. There is now 
abundant evidence that a significant proportion of RCT claims, 
in some instances in excess of 50%, cannot be replicated when 
the identical protocols are applied to target patient populations 
– including attempted replication by the original investigators.  
Failure to replicate claims from pivotal phase 3 trials undercuts 
any modeling framework and consequent cost-effectiveness 
claims.  
 
At the same time, unlike the typical design of phase 3 pivotal 
RCTs, the Minnesota guidelines ask that the protocol takes 
explicit account of comparator therapies. Rather than claims for 
new products against placebo, which are the basis for 
marketing approval, the formulary committee can insist on a 
claims assessment against the standard of care. The protocol 
does not exclude the possibility of a placebo arm if that is 
considered appropriate by the formulary committee. 
 
Consider, as a case in point, claims expressed in both clinical 
and quality of life terms. Adopting a blockchain platform, a 
protocol evaluation would allow clinical response and end-
points (at timed intervals) to be reported, but also resource 
utilization in a real world treating environment and patient 
reported quality of life outcomes (PROs). The protocol could 
not only replicate the PROs found in the original trial but could 
add further PROs to assess, for example, patient perceptions of 
response to therapy. As well, a protocol could address the fact 
that in RCTs secondary as opposed to primary outcomes are 
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typically underpowered. Rather than restricting the protocol to 
a limited sample size, noting that a blockchain protocol allows 
randomization to treatment arms, the target population can be 
expanded to allow the appropriate power for ‘secondary’ 
outcomes. It is worth noting that modeled claims for cost 
effectiveness often utilize underpowered endpoints to justify 
modeling assumptions. 
 
Compliance and Response 
The requirement for a claims assessment protocol that 
attempts to imitate the RCT parameters also has the potential 
to address the question of compliance. It is now taken as 
axiomatic that the majority of patients initiated to a range of 
therapies discontinue these within 12 to 18 months. These 
patterns stand in contrast to compliance behavior in RCTs 
where, apart from the short-term nature of many of the trials 
where discontinuation will be minimal in any case, efforts are 
made to ensure compliance. Unfortunately, one of the 
presumably unintended consequences of attempting to model 
by extrapolating from a short-term RCT, is that imaginary world 
model builders build in long-term assumptions regarding 
compliance which overstate observed behavior. A number of 
ICER reports illustrate this shortcoming 12 13 . 
 
Application of a protocol to blockchain patients, in a protocol 
that focuses on response in a real world environment (RWE) 
allows for accountability not only of compliance behavior, 
including both adherence and discontinuation, but also the 
reasons for non-compliance.  A low rate of compliance, whether 
due to poor response, adverse events or the patient simply 
seeing no reason to continue therapy, gives the formulary 
committee a powerful argument in pricing negotiations and tier 
placement. If the analysis of response suggests that certain 
characteristics are associated with poor compliance, the 
committee may recommend interventions to restrict losses due 
to non-response. This may not appeal to manufacturers, where 
the focus is on sales rather than compliance. If a sales target can 
be achieved by new patients being introduced to therapy 
matching or exceeding those dropping out, then there is little 
incentive to probe compliance behavior.  
 
Comorbidities and Older Populations 
A criticism that is often made of the typical RCT is that patients 
with comorbidities are excluded from the protocol. Excluding 
comorbidities is of particular concern in older populations; a 
group typically excluded from RCT designs. The ability to utilize 
a blockchain platform allows formulary committee to consider, 
in a protocol design whether to include comorbidities in patient 
recruitment together with older populations. The fact that a 
protocol has been agreed with the primary purpose of 
replicating RCT results does not exclude developing and 
requiring manufacturers to support other protocols in older 
populations and those with comorbidities. RWE protocols may 
be expected to qualify response claims, while providing 
external validity. 
 
The importance of being able to develop protocols in a 
blockchain environment should not be understated. Rather 
than attempting to argue, from a limited or absent evidence 
base, for the applicability of RCT claims based on  pivotal trials 
to more complex and older populations, formulary committees 
and other health decision makers are in the position of being 
able to require manufacturers to undertake studies at a 
relatively low cost and in a meaningful time frame.  
 
The Long Term 
Once a protocol is in place for a target population there is no 
reason why patients enrolled in the protocol could not be 
followed in the long-term. A manufacturer may agree, if the 
focus of the indication and claims is on the long-term why the 
protocol embedded in the blockchain could not become, in 
effect, a real-time registry.   
 
Implications for Cost-Effectiveness Claims 
Adoption by health care systems of blockchain platforms 
promise to transform the present reliance on non-evaluable 
modeled clinical and cost-effectiveness claims. Basing 
formulary decisions on submissions by manufacturers that put 
the standards of normal science to one side in favor of non-
evaluable ‘for information’ claims will be a thing of the past. 
Manufacturers will have to focus on the role of hypothesis 
testing in putting forward clinical and cost-effectiveness claims. 
Lifetime or long-term cost-per-QALY models will not be 
accepted. As noted above, the possibility of implementing 
protocols to assess claims will eliminate the need to focus on 
models if these models generate non-evaluable claims.   
 
A further casualty of the blockchain platform will be the 
plethora of statistical and mathematical techniques that have 
been developed to support lifetime models. Rather than 
imaginary constructs whose claim for relevance is based on the 
‘realism’ of their assumptions, this instrumentalist approach 
can be rejected in favor of an evidence based paradigm that 
allows patients to be tracked in real time over their course of 
treatment, generating RWE.   
 
For a health technology perspective, the blockchain offers a 
platform that moves away from the limited endpoints that 
characterize pivotal RCT protocols to an environment where 
outcomes capturing a range of PROs can be accommodated. If 
quality of life is an endpoint, then the blockchain facilitator can 
enter into contracts with patients in target groups to evaluate 
cost-per-QALY claims. If functional status is an endpoint, this 
can also be captured from the perspective of the provider. 
Monitoring functional status, for example, can provide the basis 
for assessing whether a minimal important clinical 
improvement has occurred between office visits as well as the 
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patient’s perspective on this change. The net result is the 
prospect of a quantum change in the evidence base to support 
health care. 
 
Conclusions 
The potential for blockchains to support health technology 
assessments promises a paradigmatic shift in the evaluation of 
competing pharmaceutical and device claims. Rather than 
relying on modeled claims, defended on the basis of the realism 
of their structure and assumptions, health care decision makers 
can address directly the RWE credibility or otherwise of claims. 
Evidence replaces modeled information. 
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